The latest news on culture, society and lifestyle
Provided by AGP
Ultragenyx to Participate at Investor Conferences in November
6th Annual Evercore ISI HealthCONx on November 28 in Miami
Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City
NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management, will participating in two upcoming investor conferences.
6th Annual Evercore ISI HealthCONx (Miami, FL)
- Tuesday, November 28, 2023, management will host 1x1 meetings.
Piper Sandler 35th Annual Healthcare Conference (New York City, NY)
- Wednesday, November 29, 2023, at 10:00am, Emil Kakkis, M.D., Ph.D., CEO and President, will participate in a fireside chat and host 1x1 meetings.
The live and archived webcast of the fireside chat will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
ir@ultragenyx.com
Media
media@ultragenyx.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
